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Abstract:
Background  and  aim:  Mucopolysaccharidosis  IVA  (MPS  IVA)  leads  to  skeletal  dysplasia  through  excessive  storage  of 
chondroitin-6-sulfate and keratan sulfate (KS). KS is synthesized mainly in cartilage and released into circulation, making it a   critical 
biomarker for MPS IVA to evaluate clinical course and effectiveness of therapies. Therefore, an accurate and sensitive method is 
required to measure KS levels.
Material and methods: Using sandwich ELISA and liquid chromatography tandem mass spectrometry (LC/MS/MS) assays, we 
  measured KS levels in blood and urine from MPS IVA patients and healthy controls to evaluate comparability of results. Blood (patients, 
n = 110; controls, n = 364) and urine (patients, n = 103; controls, n = 326) specimens were obtained.
Results: Plasma and urine KS measurements in patients were age-dependent and higher than age-matched controls. We observed a 
moderate correlation (r = 0.666; P , 0.001) between urine KS measurements and a weak correlation (r = 0.333; P = 0.002) between 
plasma KS measurements by ELISA and LC/MS/MS methods in patients. No correlation was found between plasma KS measurements 
in controls. The difference between KS measurements assayed by LC/MS/MS and ELISA was greater in controls than in patients. 
A moderate correlation between blood and urine KS measurements in the same individual was observed.
Conclusion: These findings indicate that both methods to measure blood and urine KS are suitable for diagnosis, monitoring therapies, 
and longitudinal assessment of the disease course in MPS IVA, but the LC/MS/MS method measures over 10 times more KS present 
in body fluids.
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Introduction
Mucopolysaccharidosis  IVA  (MPS  IVA,  Morquio 
A  disease)  is  an  autosomal  recessive  lysosomal 
storage  disease  characterized  by  deficiency  of 
N-acetylgalactosamine-6-sulfate sulfatase (GALNS, 
E.C.3.1.6.4,  MIM#  253000).  GALNS  is  one  of 
  several enzymes required for the breakdown of the 
glycosaminoglycans  (GAGs),  chondroitin-6-sulfate 
(C6S) and   keratan sulfate (KS). Deficiency of GALNS 
activity results in the build-up of C6S and KS in lyso-
somes  leading  to  progressive  skeletal  dysplasia.1–4 
  Consequently, excessive undegraded KS synthesized 
in cartilage cells is released into circulation and is 
thus an important biomarker for assessing MPS IVA.
In healthy individuals, blood KS levels rise pro-
gressively during the first 4 years of life and remain 
elevated until 12 years of age. At that time, KS lev-
els decline markedly and after 15 years of age the 
levels continue to fall gradually until they stabilize 
around age 20.5,6 Elongation of the long bones dur-
ing growth occurs by a process of endochondral ossi-
fication in which new cartilage is laid down before 
it is degraded and replaced by bone. The decline of 
KS levels after 13 years of age is consistent with the 
fact that the growth rate in normal children decreases 
after age 13. In MPS IVA patients, plasma KS levels 
peak between 5 and 10 years of age while urine KS 
levels peak between ages 0 to 5.7,8 Blood and urine 
KS levels are higher in MPS IVA patients than in age-
matched controls under 20 years of age. Urine KS 
levels remain higher in MPS IVA patients than con-
trols after 20 years of age, but plasma KS levels tend 
to normalize by age 20.6–8
Analysis  of  blood  and  urine  KS    concentrations 
is  a  useful  tool  in  assessing  the  clinical  status  of 
patients  with  MPS  IVA.  It  will  be  also  useful  in 
evaluating  response  to  treatments  such  as  enzyme 
replacement therapy (ERT), hematopoietic stem cell 
  transplantation (HSCT), substrate reduction therapy 
and  gene    therapy.  Currently,  the  clinical  trials  for 
MPS IVA by ERT are underway and investigational 
trials for HSCT are also in progress.9,10 Gene therapy 
is under development.11 Thus, a biomarker to monitor 
the efficacy of therapies is indispensable as the sec-
ondary clinical endpoint. KS is also an important bio-
marker in other disorders where cartilage catabolism 
is present, such as osteoarthritis, rheumatoid arthritis, 
and other types of MPS.12–16
Various  methods  have  been  established  for  the 
analysis  of  blood  and  urine  KS  levels,  each  with 
  different  benefits.  Thin-layer  chromatography17 
(TLC) is quick and inexpensive, yet provides poor 
quantitation and accuracy. Colorimetric analysis by 
use of dimethylmethylene blue18,19 is not satisfactory 
in  selectivity.  Inhibition  enzyme-linked  immuno-
sorbent assay12 offers accurate, reproducible results, 
yet requires multiple laborious steps. The sandwich 
ELISA method6,15 allows a faster and simpler method 
that provides high specificity to KS. Most recently, 
a liquid chromatography tandem mass spectrometry 
(LC/MS/MS) method has been developed,8,20 which 
is highly specific and sensitive to measure KS. Over-
all, the sandwich ELISA and LC/MS/MS methods 
appear most fit for accurately measuring large sam-
ple sizes. Therefore, it is important to examine the 
correlation between values measured by two differ-
ent assay systems. In this study, human plasma and 
urine KS levels from MPS IVA patients and healthy 
controls were determined by sandwich ELISA and 
LC/MS/MS  methods  to  evaluate  whether  results 
from each method are comparable. We also examine 
plasma and urine levels measured in the same indi-
vidual to test for correlation.
Materials and Methods
Sample collection
Blood (plasma) samples were obtained from 474 indi-
viduals (110 MPS IVA patients, 364 healthy controls) 
and urine samples were obtained from 429 individu-
als (103 MPS IVA patients, 326 healthy controls) after 
informed consent was obtained from each individual 
according to IRB protocol at Saint Louis University. 
One hundred twenty-one individuals provided both 
blood and urine samples (91 MPS IVA patients, 30 
healthy  controls).  Both  plasma  and  urine  samples 
were used for measurement of KS without dilution 
(2–20 µl) for ELISA and LC/MS/MS methods.
Sandwich eLISA method
Plasma and urine KS analyses were carried out as 
described  previously.5  Briefly,  analyses  were  per-
formed  with  a  commercially  available  KS-ELISA 
kit (Code: 280565) from Seikagaku (Tokyo, Japan). 
Antibody  pre-coated  plates  were  made  by  add-
ing antibody solution to each well of the microtiter 
plate. The anti-KS monoclonal antibody (5-D-4) was comparison of Lc/MS/MS and eLISA for KS
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  biotinylated using NHS-Biotin from Pierce Chemical 
(Rockford, IL, USA). Washing buffer was added to the 
microplate by multi-pipette then discarded.   Samples 
of KS standards and diluted unknown samples were 
added to the wells and incubated at 37 °C. The plate 
wells  were  then  washed  with  the  washing  buffer. 
Next, horseradish peroxidase conjugated streptavidin 
and biotinylated antibody were added to the plate and 
incubated at 37 °C. After washing the plate, substrate 
solution tetramethylbenzidine was added to the plate 
and incubated at room temperature. The reaction was 
then stopped with 1 N HCl. The absorbance was mea-
sured at 450 nm with a microplate spectrophotometer. 
KS concentration was read by applying the absor-
bances of each sample to the calibration curve.
Lc/MS/MS method
Plasma and urine KS analyses were carried out by 
the method previously described.8,20 Briefly, LC/MS/
MS (API 4000 mass spectrometer equipped with a 
turbo-ion  spray:  Applied  Biosystems,  Foster  City, 
CA) was used to analyze the disaccharides produced 
from KS. KS was digested to disaccharides by kera-
tanase II (Seikagaku Corporation, Tokyo, Japan). The 
disaccharides  were  analyzed  by  LC/MS/MS  using 
multiple reactions monitoring in negative ion mode. 
Separation was achieved by LC on a Hypercarb col-
umn  (2.0  mm  internal  diameter  (i.d.)  ×  150  mm, 
5  µm)  with  gradient  elution  by  acetonitrile–0.01 
M  ammonium  bicarbonate  (pH  10). The  flow  rate 
of the mobile phase was 0.2 ml/min. The disaccha-
ride  compositions  of  Galβ1→4GlcNAc(6S)  and 
Galβ1(6S)→4GlcNAc(6S)  were  recognized.  The 
C-6 position of the GlcNAc residue or both the Gal 
and GlcNAc residues was sulfated. Samples with KS 
concentrations were assayed in duplicate using the 
appropriate dilution.
Data analysis
The  correlation  between  ELISA  and  LC/MS/MS 
estimates was tested by a simple linear regression 
  analysis. We interpreted correlation strength as out-
lined  by  Johnston.21  Briefly,  correlations  are  inter-
preted based on r values as follows: 0.0 to 0.2, very 
weak  to  negligible  correlation;  0.2  to  0.4,  weak 
  correlation; 0.4 to 0.7, moderate correlation; 0.7 to 
0.9, strong   correlation. Data points that were greater 
than  three  standard  deviations  from  the  mean  for 
each  assay  were  considered  outliers. Analysis  was 
  performed using SPSS for Windows (version 17.0, 
SPSS Inc., Chicago, IL, USA).
Results and Discussion
Cartilage  contains  several  proteoglycans  that  are 
necessary  for  its  normal  function.  Of  these  carti-
lage  proteoglycans,  KS  contributes  to  the  struc-
tures of aggrecan, fibromodulin, and lumican.22 The 
size of KS and sulfation of galactose increase with 
age.8,23 When KS is not degraded properly, it is stored 
mainly  in  chondrocytes,  where  it  is  synthesized.24 
The    accumulation of  undegraded  KS  in  MPS  IVA 
patients leads to disruption of cartilage cells resulting 
in systemic skeletal dysplasia.25 Although pathohis-
tological examination of bone and cartilage cells is 
useful for the diagnosis and staging of MPS IVA, it is 
not feasible to obtain biopsy samples from MPS IVA 
patients. It has been suggested that measurements of 
KS concentrations in plasma and urine samples pro-
vide useful information about the diagnosis and the 
clinical status of MPS IVA patients and the efficacy 
of treatments.6–8,26,27
Two current techniques for measuring plasma and 
urine KS concentrations are based upon the sandwich 
ELISA and LC/MS/MS methods. One advantage to 
using LC/MS/MS is that this method provides higher 
sensitivity. While the current version of ELISA kit 
used in the study could not detect below 2.5 ng/ml 
of  KS,  LC/MS/MS  could  detect 0.2  ng/ml  of  KS. 
  Consequently, plasma KS in mice was measurable 
by the LC/MS/MS method.26,27 However, this ELISA 
method is advantageous over LC/MS/MS since it does 
not require large, costly equipment, making it afford-
able to be used in most labs. The results of these two 
methods have never been compared quantitatively. In 
this study, we have compared measurements obtained 
by both methods.
We  found  that  optimized  KS  calibration  curves 
gave  a  good  standard  curve  (R2  =  0.99)  between 
2.5 ng/mL and 40 ng/mL in ELISA (Fig. 1A) and 
0.2 µg/ml and 10 µg/ml in LC/MS/MS (Fig. 1B). 
Plasma  and  urine  KS  measurements  in  MPS  IVA 
patients were age-dependent and appreciably higher 
than age-matched controls (Tables 1 and 2; Figs. 2 
and  3).  Plasma  KS  concentrations  measured  by 
ELISA increased until age 10 years, at which point 
they fell gradually until normalizing around age 20 hintze et al
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years. Plasma KS   measurements by LC/MS/MS were 
highest in the first 5 years of life, and declined grad-
ually until reaching a plateau near 20 years of age. 
Urine KS concentrations were highest during the first 
5 years of life. After 5 years of age, urine KS levels 
declined until stabilizing around 20 years of age. This 
age-dependent pattern was observed with both ELISA 
and LC/MS/MS urine KS measurements.
Plasma and urine KS levels in the same individual 
were  also  compared.  A  moderate  correlation  was 
Table 1. Plasma KS level.
Age Mean Ks sD Maximum Minimum n Average age
plasma Ks (μg/ml) by eLIsA method
control (all ages) 0.128 0.076 0.365 0.003 212 19.2
 . 0, #5 y 0.089 0.067 0.353 0.003 90 0.9
 . 5, #10 y 0.237 0.088 0.365 0.048 12 8.7
 . 10, #15 y 0.185 0.067 0.328 0.086 11 13.1
 . 15 y 0.143 0.060 0.352 0.015 99 37.8
MPS IVA (all ages) 0.505 0.297 1.388 0.082 109 12.9
 . 0, #5 y 0.565 0.264 1.112 0.082 29 3.0
 . 5, #10 y 0.686 0.294 1.388 0.128 31 7.5
 . 10, #15 y 0.463 0.306 1.158 0.177 17 12.5
 . 15 y 0.297 0.174 0.717 0.089 32 27.2
plasma Ks (μg/ml) by Lc/Ms/Ms method
control (all ages) 1.803 0.757 6.189 0.329 165 13.6
 . 0, #5 y 1.843 0.634 4.555 0.394 77 1.4
 . 5, #10 y 1.669 0.663 3.349 0.329 23 7.8
 . 10, #15 y 1.813 1.465 6.189 0.428 18 12.9
 . 15 y 1.801 0.604 3.717 0.676 47 36.7
MPS IVA (all ages) 5.723 3.072 14.076 0.630 85 12.1
 . 0, #5 y 7.445 3.042 13.891 1.738 25 3.0
 . 5, #10 y 6.281 3.101 14.076 0.630 25 7.1
 . 10, #15 y 5.476 2.652 9.632 1.788 14 12.7
 . 15 y 3.173 1.207 5.329 1.343 21 28.6
Figure 1. Standard curve for the KS eLISA and Lc/MS/MS. A) Standard curve for the KS eLISA. For validation, two different KS concentration quality 
  control samples were prepared (control KS was purchased from Seikagaku co. code.400760). The absorbances (minus blank) were plotted using KS (2.5, 
5.0, 10.0, 20.0, 40.0 ng/mL) standards. B) Standard curve for the KS Lc/MS/MS. For validation, two different KS concentration quality control samples were 
prepared (control KS was purchased from Seikagaku co. code.400760). The corrected KS counts (KS counts in the analyte peak area divided by IS counts) 
were plotted using KS (0.2, 0.5, 1.0, 2.0, 4.0, 6.0, 10.0 µg/mL) standards (IS, chondrosine, was purchased from Seikagaku co. code.400430).
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Table 2. Urine KS level.
Age Mean Ks sD Maximum Minimum n Average age
Urine Ks (mg/g creatinine) by eLIsA method
control (all ages) 0.209 0.165 1.240 0.000 179 11.8
 . 0, #5 y 0.241 0.185 1.240 0.000 104 1.2
 . 5, #10 y 0.235 0.149 0.485 0.068 13 7.9
 . 10, #15 y 0.245 0.154 0.618 0.052 13 12.7
 . 15 y 0.127 0.079 0.418 0.029 49 35.1
MPS IVA (all ages) 7.741 6.600 27.200 0.083 100 13.3
 . 0, #5 y 12.384 6.610 25.700 2.600 23 3.2
 . 5, #10 y 10.464 6.676 27.200 0.431 31 7.7
 . 10, #15 y 4.612 3.372 13.900 0.083 17 12.6
 . 15 y 2.983 3.180 13.900 0.114 29 27.8
Urine Ks (mg/g creatinine) by Lc/Ms/Ms method
control (all ages) 8.943 7.640 34.589 0.774 134 6.5
 . 0, #5 y 11.275 7.967 34.589 1.992 94 1.7
 . 5, #10 y 4.380 1.180 5.835 2.521 7 8.7
 . 10, #15 y 3.903 2.256 9.547 1.205 19 11.8
 . 15 y 2.413 1.345 4.596 0.774 14 31.0
MPS IVA (all ages) 72.163 50.949 205.818 2.937 58 13.9
 . 0, #5 y 141.588 32.684 205.818 100.964 9 2.8
 . 5, #10 y 82.840 48.704 187.770 2.937 21 7.7
 . 10, #15 y 55.165 33.721 136.056 15.057 11 12.8
 . 15 y 33.216 19.144 70.882 3.644 17 28.1
observed  between  plasma  and  urine  KS  levels  in 
MPS  IVA  patients  when  measured  by  LC/MS/MS 
(r = 0.469; P = 0.004; Fig. 4A) as well as by ELISA 
(r = 0.457; P , 0.001; Fig. 4B). The data were insuffi-
cient to establish age-dependent correlations between 
plasma and urine KS levels.
We observed a moderate correlation between urine 
KS measurements assayed by ELISA and LC/MS/MS 
methods in MPS IVA patients (r = 0.666; P , 0.001; 
Fig. 4C). The correlation between urine KS measure-
ments by both methods was strong in patients over 
age 15 (r = 0.793; P , 0.001; n = 18), and moderate 
in the 5–55 age group (r = 0.502; P = 0.005; n = 30). 
We could not establish a correlation in the 0–5 age 
group as a result of insufficient data. A weak corre-
lation (r = 0.333; P = 0.002; Fig. 4D) was observed 
between plasma KS measurements assayed by both 
methods for MPS IVA patients. Age-dependent cor-
relations between plasma KS measurements assayed 
by each method were not significant since there were 
a limited number of observations in each age group.
Plasma  KS  measurements  by  ELISA  and 
LC/MS/MS  were  also  compared  in  healthy  con-
trols. The   correlation between methods was negligi-
ble (r = −0.095; P = 0.658; Fig. 4E). The data were 
  insufficient to compare ELISA and LC/MS/MS urine 
KS measurements in healthy controls.
Urine KS levels measured by LC/MS/MS in MPS 
IVA patients were 9.3 times higher than those mea-
sured by ELISA, while KS levels measured by LC/
MS/MS in healthy controls were 42.8 times higher 
than those by ELISA. Plasma KS levels measured 
by LC/MS/MS in MPS IVA patients were 11.3 times 
higher than by ELISA, and 14.1 times higher for con-
trols. The largest difference between ELISA and LC/
MS/MS measurement values in plasma and urine KS 
were observed in the 0–5 years of age group, all other 
age groups being fairly homogeneous.
Plasma and urine KS levels in MPS IVA patients 
measured by ELISA in this study are age-dependent 
and comparable to those reported previously.6,8 Age-
dependent  urine  KS  levels  in  MPS  IVA  patients 
measured by LC/MS/MS have not been previously 
reported. We found that urine KS measurements by 
LC/MS/MS follow a pattern similar to those found by 
the ELISA method. Plasma KS measurements by LC/
MS/MS were age-dependent and comparable to those 
previously reported.7 There is currently no explanation 
why blood and urine KS levels follow different age-
dependent patterns. One hypothesis is that the origin hintze et al
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of blood and urine KS is different. While blood KS 
is derived directly from cartilage cells, only smaller 
KS molecules are filtered in the kidney and excreted 
in urine. Another hypothesis is that urine concentra-
tion is reflected by age. Infants, who will not control 
urine concentration adequately, could have higher KS 
values corrected by lower creatinine level. Despite 
the difference in age-dependent patterns, our results 
reveal  a  moderate  correlation  between  blood  and 
urine KS levels measured in the same individual.
The moderate correlation between ELISA and LC/
MS/MS urine KS measurements in MPS IVA patients 
indicates that results from each assay are comparable. 
Plasma KS measurements by ELISA are less compa-
rable to those by LC/MS/MS than urine KS measure-
ments. Plasma KS measurements by ELISA and LC/
MS/MS in healthy individuals showed no correlation. 
We could not conclude whether ELISA and LC/MS/
MS urine KS measurements are correlated in controls 
because of data limitations. The reason for the varia-
tion in correlation strengths for each regression could 
be due to a difference in the ability of each assay to 
detect non-sulfated galactose (see below).
The GALNS enzyme catalyzes the hydrolysis of 
the 6-sulfate group of the D-galactose 6-sulfate unit 
of KS. Therefore, the level of GALNS enzyme   activity 
Figure 2. concentrations of plasma and urine KS of patients with MPS IVA and normal individuals as measured by eLISA and Lc/MS/MS. A) Plasma KS 
results by eLISA of 109 specimens from MPS IVA individuals and 212 normal individuals are plotted with respect to age. B) Urine KS results by eLISA of 
100 specimens from MPS IVA individuals and 179 normal individuals are plotted with respect to age. c) Plasma KS results by Lc/MS/MS of 85 specimens 
from MPS IVA individuals and 165 normal individuals are plotted with respect to age. D) Urine KS results by Lc/MS/MS of 58 specimens from MPS IVA 
individuals and 134 normal individuals are plotted with respect to age.
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determines  the  ratio  of  Galβ1(6S)→4GlcNAc(6S) 
to Galβ→4GlcNAc(6S) that is present in blood and 
urine. Thus, this ratio is higher in MPS IVA patients, 
where the GALNS enzyme is deficient, than in healthy 
individuals.8 The ratio of Galβ1(6S)→4GlcNAc(6S) 
present in blood varies by age. Briefly, when con-
trol  subjects  and  MPS  IVA  patients  in  several 
age  ranges  (2–5  years,  5–10  years,  10–15  years, 
and over 15 years) were compared, their ratios of 
Galβ1(6S)→4GlcNAc(6S)  to  Galβ→4GlcNAc(6S) 
were  as  follows:  control  subjects  vs.  MPS  IVA 
patients, 17.5% vs. 19.7%; 17.3% vs. 21.3%; 17.6% 
vs. 28.5%; 23.6% vs. 23.1%, respectively.8 The ratio 
of Galβ1(6S)→4GlcNAc(6S) increases with age espe-
cially in MPS IVA patients. The compositional ratio of 
Galβ1(6S)→4GlcNAc(6S)  to  Galβ→4GlcNAc(6S) 
present in urine has not been reported in previous and 
current studies.
The  monoclonal  antibody  used  for  the  ELISA 
in  the  present  study  involves  sulfated  hepta-  or 
larger  oligosaccharides  of  KS28  and  is  specific  for 
Galβ1(6S)→4GlcNAc(6S),  meaning  both  galac-
tose and N-acetyl-glucosamine must be sulfated for 
recognition.29  Hence,  the  ELISA  method  does  not 
reflect total KS quantification in a specimen. Mean-
while, the LC/MS/MS method provides more com-
plete  quantification  of  KS  by  utilizing  keratanase 
II for KS digestion. Keratanase II recognizes both 
Galβ→4GlcNAc(6S) and Galβ1(6S)→4GlcNAc(6S) 
disaccharides, in which N-acetyl-glucosamine is sul-
fated. All KS molecules digested by keratanase II turn 
into disaccharides. Thereby, in spite of the original 
size of KS molecule, it is measurable. Thus, the LC/
MS/MS method is more efficient at measuring KS 
contained in a specimen than the ELISA method.
As  previously  noted,  LC/MS/MS  measure-
ments  were  markedly  higher  than  ELISA  mea-
surements.  However,  the  difference  between  LC/
MS/MS  and  ELISA  measurements  was  greater  in 
healthy controls than in MPS IVA patients. This is 
due to GALNS activity in healthy controls produc-
ing more Galβ→4GlcNAc(6S) component which is 
not detectable by ELISA. Conversely, a deficiency 
in GALNS activity in MPS IVA patient reduces the 
amount  of  Galβ→4GlcNAc(6S)  component  that  is 
not measured by ELISA. The greatest gap between 
ELISA  and  LC/MS/MS  was  observed  in  urine 
measurements  in    controls.  This  suggests  that  the 
Figure 3. comparison of plasma and urine KS levels between MPS IVA patients and normal individuals by eLISA and Lc/MS/MS methods. A) Plasma KS 
results by eLISA. B) Plasma KS results by Lc/MS/MS. c) Urine KS results by eLISA. D) Urine KS results by Lc/MS/MS. Plasma and urine KS levels by 
both methods are significantly higher in MPS IVA patients at any age.
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Figure 4. correlation in KS concentrations. A) correlation between plasma and urine KS as measured by Lc/MS/MS in MPS IVA patients (n = 36, 
P = 0.004). B) correlation between plasma and urine KS as measured by eLISA in MPS IVA patients (n = 87, P , 0.001). c) correlation between 
Lc/MS/MS and eLISA methods by urine KS levels in MPS IVA patients (n = 55, P , 0.001). D) correlation between Lc/MS/MS and eLISA methods 
by plasma KS levels in MPS IVA patients (n = 83, P = 0.002). e) correlation between Lc/MS/MS and eLISA methods by plasma KS in healthy controls 
(n = 24, P = 0.658).comparison of Lc/MS/MS and eLISA for KS
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Galβ1(6S)→4GlcNAc(6S)  to  Galβ→4GlcNAc(6S) 
ratio is lowest in the urine of healthy controls. Thus, 
the  ELISA  assay  does  not  reflect  the  total  urine 
KS level in healthy controls. The smallest gap was 
observed in MPS IVA urine measurements, suggest-
ing that the ratio between Galβ1(6S)→4GlcNAc(6S) 
and Galβ→4GlcNAc(6S) is high in patients urine. 
Overall,  the  gap  between  ELISA  and  LC/MS/MS 
measurements was highest in the 0–5 age group in 
controls and patients, and was fairly uniform in all 
other age groups. These results support the previous 
findings that the sulfation of KS increases with age.8,23 
Therefore, the ELISA method may be less effective at 
measuring total KS in children under age 5 years than 
in older individuals. The Galβ1(6S)→4GlcNAc(6S) 
to Galβ→4GlcNAc(6S) ratio is a significant factor 
to consider when comparing ELISA and LC/MC/MC 
assay measurements, but each method is suitable for 
measuring urine and plasma KS levels in MPS IVA 
patients.
Our findings suggest that both blood and urine 
KS are a good biomarker for MPS IVA. Blood KS 
has a narrower ranged value and will be directly 
reflected for cartilage disruption and/or repair after 
therapy. Dried blood spot can be a quite useful tool 
for  transport  of  samples  and  newborn  screening. 
Meanwhile, urine KS has a broad ranged value and 
will be indirectly reflected for cartilage condition. 
Advantage to use urine KS is less invasive although 
creatinine has to be measured for correction. Why 
urine KS in MPS IVA patients over 20 years old can 
not be normalized remains unanswered. It will be of 
great interest to understand the origin of blood and 
urine KS and the metabolism pathway of KS from 
cartilage to urine.
In  conclusion, we  have suggested that both the 
ELISA and LC/MS/MS methods of measuring urine 
KS in MPS IVA patients yield comparable results, 
although  plasma  KS  results  are  less  comparable 
between methods. The ELISA method is less effec-
tive at measuring total KS. However, both methods 
have reproducibility, accuracy, and high throughput 
for MPS IVA patients. Overall, both methods should 
provide a useful tool to measure blood and urine KS 
to assess the clinical status of MPS IVA patients and 
to measure the response to treatments such as ERT, 
HSCT, SRT, and gene therapy.
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